Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM)

被引：47

作者：

Klabatsa, A ^{[1
]}

Sheaff, MT

Steele, JPC

Evans, MT

Rudd, RM

Fennell, DA

机构：

[1] Royal London Hosp, Inst Pathol, Queen Mary Sch Med & Dent, London E1 1BB, England

[2] Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Queen Marys Sch Med & Dent, London EC1A 7BE, England

[3] Belfast City Hosp, No Ireland Thorac Oncol Res Grp, Ctr Canc Res, Belfast BT9 7AD, Antrim, North Ireland

来源：

LUNG CANCER | 2006年 / 51卷 / 01期

关键词：

hypoxia-inducible factor 1 alpha (HIF-1 alpha); malignant pleural mesothelioma (MPM); hypoxia; apoptosis; microvessel density (MVD); angiogenesis;

D O I：

10.1016/j.lungcan.2005.07.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant pleural mesothelioma (MPM) is a highly chemoresistant cancer with a poor prognosis. Hypoxia is a specific property of solid tumours, contributes to tow apoptotic potential, and can be selectively targeted by bioreductive drugs. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) is a subunit of a heterodimeric transcription complex that regulates several genes associated with tumour progression and antiapoptosis. In this study, we measured for the first time the expression of HIF-1 alpha in MPM. Our results show that HIF-1 alpha is commonly expressed in MPM but not in normal mesothelium, consistent with the presence of hypoxia. HIF-1 alpha does not appear to predict survival; however, this study suggests that bioreductive drugs should be investigated in clinical trials of MPM. (C) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：53 / 59

页数：7

共 23 条

[1] Cancer - Cues for migration [J].

Bernards, R .

NATURE, 2003, 425 (6955) :247-248

[2] Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma [J].

Fennell, DA ;

Steele, JPC ;

Shamash, J ;

Sheaff, MT ;

Evans, MT ;

Goonewardene, TI ;

Nystrom, ML ;

Gower, NH ;

Rudd, RM .

LUNG CANCER, 2005, 47 (02) :277-281

[3] c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-lot dependent [J].

Giatromanolaki, A ;

Koukourakis, MI ;

Simopouios, C ;

Polychronidis, A ;

Gatter, KC ;

Harris, AL ;

Sivridis, E .

CLINICAL CANCER RESEARCH, 2004, 10 (23) :7972-7977

[4] Hypoxia inducible factor 1α and 2α overexpression in inflammatory bowel disease [J].

Giatromanolaki, A ;

Sivridis, E ;

Maltezos, E ;

Papazoglou, D ;

Simopoulos, C ;

Gatter, KC ;

Harris, AL ;

Koukourakis, MI .

JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (03) :209-213

[5] Hypoxia - A key regulatory factor in tumour growth [J].

Harris, AL .

NATURE REVIEWS CANCER, 2002, 2 (01) :38-47

[6] Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells [J].

Hayashi, M ;

Sakata, M ;

Takeda, T ;

Yamamoto, T ;

Okamoto, Y ;

Sawada, K ;

Kimura, A ;

Minekawa, R ;

Tahara, M ;

Tasaka, K ;

Murata, Y .

JOURNAL OF ENDOCRINOLOGY, 2004, 183 (01) :145-154

[7] APOPTOSIS AND CANCER-CHEMOTHERAPY [J].

HICKMAN, JA ;

POTTEN, CS ;

MERRITT, AJ ;

FISHER, TC .

PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES, 1994, 345 (1313) :319-325

[8] The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050 [J].

Hodgson, JT ;

McElvenny, DM ;

Darnton, AJ ;

Price, MJ ;

Peto, J .

BRITISH JOURNAL OF CANCER, 2005, 92 (03) :587-593

[9] Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway [J].

Huang, LE ;

Gu, J ;

Schau, M ;

Bunn, HF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :7987-7992

[10] HIFα targeted for VHL-mediated destruction by proline hydroxylation:: Implications for O2 sensing [J].

Ivan, M ;

Kondo, K ;

Yang, HF ;

Kim, W ;

Valiando, J ;

Ohh, M ;

Salic, A ;

Asara, JM ;

Lane, WS ;

Kaelin, WG .

SCIENCE, 2001, 292 (5516) :464-468

← 1 2 3 →